Biotricity continues its strategic expansion with the announcement of its latest partnership in neurology to conduct cardiac screenings in patients suffering from neurological issues.
There are over 1,000 neurological disorders and over 100 million Americans suffering from at least 1 neurological issue. Alzheimer's, Parkinsons, and other dementias are just a few such conditions that lead to increased cardiovascular risk. Many of these patients are screened late, leading to an increase in costs and higher patient risk. Biotricity is focused on providing earlier screenings to patients with co-morbidities, reducing costs while improving the quality of care.
"Biotricity is proud to announce this expansion as the first step in its strategy to build out a broader cardiac screening network to support patients with co-morbidities," said Waqaas Al-Siddiq, Ph.D., Founder, Chairman, and CEO of Biotricity. "This milestone will serve as a foundation for our expansion strategy and enhance our visibility and market reach within the healthcare industry."
Cardiologists are overwhelmed with too many patients, unable to service all those that need their expertise. With the increase in chronic conditions, cardiologists are receiving referrals from a variety of specialists, including neurologists, pulmonologists, nephrologists, and endocrinologists, to name a few. All these patients have increased cardiac risk but often receive cardiac diagnoses late.
Biotricity's approach is to build strategic partnerships to help deliver cardiac screenings by the referring physician. Patients will be screened earlier and referred to cardiologists to receive care as opposed to being referred for screenings. This approach will not only reduce costs but also improve outcomes and the quality of care. Most importantly, it will optimize the time for all physicians involved, enabling them to service more patients.
This strategic approach will expand Biotricity's market opportunity while focusing on better patient outcomes. By partnering with specialty groups already focused on the target patient population, Biotricity can achieve much faster market access. This partnership alone will give Biotricity an opportunity to access the neurology market, comprised of over 100 million Americans and over 16,000 neurologists. Biotricity is focused on building out similar partnerships in other specialty areas where patients have increase cardiac risk factors and require cardiac screenings.
